Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

Rhea-AI Summary

Arvinas, a clinical-stage biopharmaceutical company, announced that its President and CEO, John Houston, and Chief Scientific Officer, Ian Taylor, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on February 11 at 4:30 p.m. ET. The event will be accessible via a live audio webcast on Arvinas’ website. The company focuses on developing innovative therapies that target disease-causing proteins, with ongoing clinical programs for ARV-110 and ARV-471 aimed at treating advanced forms of prostate and breast cancer respectively.

News Market Reaction – ARVN

-0.30%

-0.30% Session move

In the trading session that priced this news, ARVN declined 0.30%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET.

A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com

FAQ

What is Arvinas presenting at the Guggenheim Healthcare Talks on February 11?

Arvinas will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day.

Who will represent Arvinas at the Oncology Day event?

John Houston, President and CEO, and Ian Taylor, Chief Scientific Officer, will represent Arvinas.

How can I access the Arvinas presentation live on February 11?

The presentation will be available via a live audio webcast on Arvinas' website.

What are the main clinical programs Arvinas is currently working on?

Arvinas is developing ARV-110 for prostate cancer and ARV-471 for ER+/HER2- breast cancer.

What is the focus of Arvinas as a biopharmaceutical company?

Arvinas focuses on creating therapies that degrade disease-causing proteins using its PROTAC technology.